Millipore and Novo Nordisk expand human insulin supply agreement
US-based Millipore Corporation is expanding its agreement with Novo Nordisk to provide the biopharmaceutical market with recombinant human insulin, a key cell culture supplement used to manufacture biologic drugs.
US-based Millipore Corporation is expanding its agreement with Novo Nordisk to provide the biopharmaceutical market with recombinant human insulin, a key cell culture supplement used to manufacture biologic drugs.
Under the terms of the agreement, Millipore will have exclusive worldwide rights to market and sell Novo Nordisk's recombinant human insulin, branded by Millipore as Incelligent SG and Incelligent AF, for cell culture media applications. Incelligent is said to be the world's leading insulin product used in the manufacture of numerous biologic drugs.
Incelligent is available in a standard grade and in an animal-free version, which uses no animal-derived products in its manufacturing process. The use of animal-free supplements reduces risk and eases regulatory concerns for biopharmaceutical manufacturers.
The current long-term supply agreement between Millipore and Novo Nordisk has been extended for several years, ensuring that biopharmaceutical manufacturers will have a guaranteed, secure supply of insulin to use in the production of biologic drugs and the development of new cell lines. The two companies have partnered together for the past 15 years and have the resources and stability to support long-term manufacturing requirements for cell culture supplements.